

REMARKS

The Examiner has required restriction in the above-identified application as follows:

Group I: Claims 1-14, drawn to assay method;

Group II: Claims 15-26, 33-46, drawn to chemical conjugation processes and products; and

Group III: Claims 27-32, drawn to glycopeptides.

In response to the restriction requirement, Applicants hereby elect, with traverse, Group I, Claims 1-14.

The above election has been made with traverse. In particular, Applicants respectfully submit that examination of all currently pending claims would not pose an undue burden on the Examiner. Section 803 of The Manual of Patent Examining Procedure states that “[i]f the search and examination of an entire application can be made without serious burden, the Examiner must examine it on the merits, even though it includes claims to independent or distinct inventions.” Applicants therefore respectfully request examination of all currently pending claims.


In responding to the restriction requirement, the Applicants take no position regarding whether the claims of the various groups identified in the Official Action define distinct inventions.

CONCLUSION

Applicants submit that the application is now in condition for examination on the merits. Early notification of such action is earnestly solicited. If any issues remain which the Examiner feels may be best resolved through a personal or telephonic interview, the Examiner is respectfully requested to contact Applicants' counsel, Christopher W. Raimund at (202) 861-3896.

Respectfully submitted,

DLA PIPER RUDNICK GRAY CARY U.S. LLP



Steven B. Kelber
Registration No. 30,073
Attorney of Record

1200 Nineteenth Street, N.W.
Washington, D.C. 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

Christopher W. Raimund
Registration No. 47,258